

EQUITA GROUP

Company report

Buy (maintained)

18 November 2019 - 5:30 PM

MARKET PRICE: EUR2.60

TARGET PRICE: EUR3.37 (from EUR3.50)


Investment Banking

Data		
Shares Outstanding (m):	45	5.5
Market Cap. (EURm):	- 11	8.2
Enterprise Value (EURm):	N	IA
Free Float (%):	36.	.7%
Av. Daily Trad. Vol. (m):	0.	06
Main Shareholder:	Managem	ent 54.3 %
Reuters/Bloomberg:	EQUI.MI	EQUI IM
52-Week Range (EUR)	2.43	3.45
Source: FactSet, UBI Banca estimates		

Performance

	lm	3m	I2m
Absolute	3.2%	0.4%	-21.8%
Rel. to FTSE IT	-1.8%	-16.7%	-44.2%
Source: FactSet			

Graph area Absolute/Relative 12 M



Massimo Vecchio Senior Analyst massimiliano.vecchio@ubibanca.it Tel. +39 02 62753016

Dario Fasani Analyst dario.fasani@ubibanca.it Tel. +39 02 62753014

www.ubibanca.com/equity-research

Stabilization in 3Q, ambitious BP issued

In the third quarter of 2019 Equita financials showed, finally, some signs of stabilization with a EUR1,6 million net profit, +4% vs. the 3Q18 figure. Revenues were up YoY thanks to market shares gains in Global Markets and despite negative m-t-m of Equita's SPAC. In the wording of the 3Q19 release it seems clear how management perceives a stabilization in market conditions, specifically in Investment Banking. This perception and the reassuring 3Q19 lead Equita to confirm its 2019 guidance. Management went further by announcing a mid-long term guidance that points to EUR75 million revenues in 2022 up 43% from the EUR52.5 million we estimate for 2019. The plan envisages also M&A as an eventual accelerator towards midlong term targets. We don't rule out that the plan exercise will ease itself this M&A effort. We are reducing our 2019-22 estimates by 12.2% but reiterating our positive stance supported by the signs of stabilization supplied by 3Q19 and reinforced by some M&A appeal.

- > **3Q19: Global markets impressive performance**. Against mild growth in MTA third-party traded volumes (+4%), GM commissions grew 25% YoY (entirely organic). Market share gains were the name of the game: a 9.4% share in Equities, 6.4% in bonds and 8.1% in Equity Options for imply, respectively, +280bps, +220bps and +280bps vs. 9MYTD 2018. With Investment Banking flat YoY, this was enough to more than compensate the 50% YoY decline in AAM (explained by a EUR0.8 million non-recurring charge on the SPAC. The last, considering that Equita decided to reimburse investors).
- > Mid-long term plan: organic and inorganic. GM is seen growing to EUR34 million (45% of total sales) thanks to cross-selling and diversification. IB, the most challenging target of the entire BP, is seen at least doubling 2019 revenues and reach a EUR30/34 million mark (40-45% of total). AAM, where AuM should reach the EUR2 billion level, is seen doubling too, reaching a EUR8/11 million mark (10% of total). While targets are organic, and based on future business initiatives, the plan could be accelerated by M&A and/or partnerships. Management went as far as saying that it could use part of the excess capital, leverage capacity or even opening up the capital to new partners. While management during roadshows never ruled out external growth, the fact that now it is explicitly written down implies a higher conviction which could be a propeller also for the share price.
- > **BUY** reiterated, tp to **EUR3.37**. Despite peers re-rated in the past 2 months, the cut in estimates brought our TP down by 4%. FY2019 results will be useful to understand the amount of performance fees and the dividend, which we expect at the high end of the EUR0.18-0.20 guidance. Notwithstanding extremely harsh market conditions in 1H19 which depressed the share, Equita growth resumption in 2020 underpins our positive stance.

Financials EURm (ex. treasu	ıry share	s)		Ratios (ex treasury shs), priced on 15-11-19					
	2018A	2019E	2020E	2021E		2018 A *	2019E	2020E	2021E	
Revenues	59,8	52,5	57,6	61,7	P/E (x)	13,2	14,5	11,5	10,1	
Profit Before Taxes	15,6	11,8	14,8	16,9	P/BV (x)	1,8	1,5	1,5	1,5	
Net Income	11,0	8,1	10,3	11,7	TCR (%)	25,2%	25,8%	25,1%	24,5%	
Net Income Adjusted	12,0	8,1	10,3	11,7	CETI ratio (%)	25,2%	25,8%	25,1%	24,5%	
BVPS (EUR)	1,76	1,72	1,75	1,78	Dividend yield (%)	6,9%	7,7%	8,5%	9,4%	
EPS (EUR)	0,24	0,18	0,23	0,26	Payout ratio (%)	90,7%	111,9%	97,1%	95,0%	
DPS (EUR)	0,22	0,20	0,22	0,25	Net Inc./Sales (%)	18,4%	15,5%	17,9%	19,0%	
Source: Company data Ul	BI Banca esti	mates			Source: Company date	a UBI Banca e	st *Based o	on 2018 ava	brice	

1

Key Financials

(EURm)	2018A	2019E	2020E	2021E
Revenues	59,8	52,5	57,6	61,7
Profit Before Taxes	15,6	11,8	14,8	16,9
Net profit	11,0	8,1	10,3	11,7
Net Profit - Adjusted	12,0	8,1	10,3	11,7
Shareholders' Equity	80,1	78,2	79,4	81,1
RWA	218,2	212,9	224,9	236,2

Source: Company data, UBI Banca estimates

Key Profitability Drivers

(%)	2018A	2019E	2020E	2021E
RoE	13,8%	10,4%	13,0%	14,5%
RoTE	20,4%	14,8%	19,1%	21,6%
Cost/Income	73,9%	77,6%	74,3%	72,7%
Comp/Revenues	45,8%	46,0%	45,2%	45,3%

Source: Company data, UBI Banca estimates

Key Valuation Ratios

(x)	2018A*	2019E	2020E	2021E
P/E (x)	13,2	14,5	11,5	10,1
P/E Adjusted (x)	12,2	14,5	11,5	10,1
P/BV (x)	1,8	1,5	1,5	1,5
P/TBV (x)	2,2	1,8	1,9	1,8
Dividend Yield (%)	6,9%	7,7%	8,5%	9,4%
RoE/CoE (x)	1,97	1,48	1,85	2,06

Source: Company data, UBI Banca estimates

Growth Rates

(%)	2018A	2019E	2020E	2021E
Revenues	10,9%	-12,2%	9,7%	7,2%
Profit Before Taxes	1,6%	-24,5%	25,8%	13,8%
Net Income	0,2%	-26,3%	26,7%	13,8%
Net Income Adjusted	6,6%	-32,0%	26,7%	13,8%

^{*} Based on 2018 average price



Recent developments

- > 3Q19 broadly in line with our estimates, worth noting that results quality was high. Revenues surprised and were 6% above our estimates with the bulk of the surprise coming from Global Markets, with IB broadly aligned and AAM well below our expectations. The latter was hit by EUR0.8 million mark-to-market of the SPAC booked also in view of the fact that EPS2 will be liquidated (as written here below). Net of that AAM revenues would have amounted to EUR1.2 million or 50% higher YoY (and above our estimates by the same amount). The usual tight control on costs translated the EUR0.7 million revenues surprise to the pre-tax level. Higher than expected taxes brought the net income below our estimates but, the quality of the results (a top line beat and a non-recurring charge) was high.
- > Investment Banking revenues stabilized in 3Q19 and comparison got (and will get) easier. IB revenues were down 8% YoY and were aligned with our estimates for the first time since we cover the stock. This is a remarkable result when looking at the end-markets conditions: 9M19, M&A volumes were down 15% YoY, ECM deals below EUR1 billion were down 73% YoY while DCM (high-yields and not-rated) were down 35%.
- > Equita launched a second private debt fund and will liquidate EPS2. Notable events announced after the closure of the quarter were: a) the launch of a second private debt fund. The fund has a target size of EUR200 million and will have an investment strategy in line with its predecessor (Equita Private Debt Fund: invest in senior unitranche and subordinated bonds in sponsor-led transactions, with a maturity of 5 to 7 years and a bullet repayment structure). Expected returns are in line with the ones achieved by EPD, now fully deployed with an expected gross return of around 9.5%; b) EPS2 (Equita's SPAC) will be liquidated and shareholders will be reimbursed sooner than expected. While this outcome is different from what was the original aim, it shows how the company aims to be fair with the market.

Figure 1 - 3Q19 and 9M19 results

rigare i Sqrii and iiii	7 1034103							
(EURm)	3Q18A	3Q19A	YoY chg.	3Q19E	A/E change	9M18A	9M19A	YoY chg.
Global Markets	6,0	7,5	25,0%	6,3	19,2%	22,9	24,6	7,4%
Inv Banking	5,0	4,6	-8,1%	4,5	2,2%	22,4	10,4	-53,6%
AAM	0,8	0,4	-49,2%	1	-60,0%	3,2	3,1	-3,1%
Net Revenues	11,8	12,5	6,0%	11,8	6,0%	48,5	38,0	-21,6%
Personnel Costs	5,5	5,8		5,0		22,8	17,4	
Administrative expenses	4,5	4,4		4,5		12,9	12,5	
Profit before Taxes	1,7	2,4	37,8%	2,3	4,3%	12,8	8,2	-36,1%
Group Net profit	1,56	1,64	5,0%	2,1	-20,4%	9,1	5,6	-38,5%
margin %	13,2%	13,1%		17,5%		18,8%	14,7%	
Group Net profit Adj.	1,56	1,64	5,0%	2,1	-20,4%	9,1	5,6	-38,5%
margin %	13,2%	13,1%		17,5%		18,8%	14,7%	
Group Net Equity	83,2	73,8	-11,3%	73,8	0,0%	83,2	73,8	-11,3%





Financial Projections

- > 2019 guidance confirmed. Our estimates revised down (performance fees not included yet quite likely to materialize). While management confirmed the 2019 guidance (which was calling for a 2H19 in line with 1H19), undoubtedly 3Q19 sounded better than expected. Furthermore, both guidance and our estimates do not include any performance fees which, at this stage, seems extremely visible. Our new estimates see: a) 2019 revenues at EUR52.5 million (slightly above the EUR50.8 million of the guidance and due to the surprise in 3Q19); b) a net income of EUR8.1 million (broadly aligned with the guidance); c) a dividend at the high end of the EUR0.18-0.20 included in the guidance. If the market stabilization will persist in fact, regardless of the 2019 Net Income, confidence in what 2020 could bring should push towards the EUR0.20 dividend.
- > 2022 targets: challenging but achievable. After a tough year on the P&L side and, at the same time, a prolific year in terms of business initiatives, the mid-long term business plan was presented to the market, in our view, to give more visibility on what the shape of the group will be once all those initiatives will reach a cruise speed. Looking at the targets by division is helpful in better understanding how the business, operationally, should evolve: a) Global market: end-markets are still seen tough and the revenues growth toward the high end of the EUR30/34 million range (between 40% and 45% of total revenues) should be driven by cross-selling and diversification; b) IB: the plan assumes a EUR30/34 million revenues target (again 40-45% of total) which means at least doubling from the EUR15 million expected for this year, but the 2022 target is more realistic if seen in the context of the EUR26 million achieved only one year ago. Enlargement of the product offer and, likely, of the team should support this growth; c) AAM: the launch of the SGR should ease the AuM growth towards the EUR2 billion targeted with revenues being 10% of total (EUR8-11 million). Some AuM will come from asset classes already in house while others (ELTIF for instance) from the entrance in new niches.
- > Balance between organic and in-organic growth, capital and dividends. The press release mentions that the plan is built on a relatively stable market framework and on a stand-alone basis. This means it includes new hirings (also of entire teams), commercial agreements and new product launches. The guidance does not include external growth which however is targeted: while a 20% TCR is achievable (and coherent with EUR20 million co-investment in new products), a 15% is a level considered still acceptable with the balance to be used, eventually, for M&A. Management went as far as saying that they are available, with the support of the main shareholders, to open the share capital to strategic partners with the aim of accelerating the growth trajectory. Last, but not least, the plan envisage a significant Corporate Social Responsibility side which should have evident benefits on the company's stakeholders and should put Equita at par, on this front, with larger companies.
- > Our new 2020-22 estimates: While the Net Income/Revenues target of 20% is absolutely achievable (this level was reached in 2018 already, scale and efficiencies could even justify an higher number) obviously the revenues target is where the challenge lies. Our new estimates are broadly aligned with the company business plan with the exception of the IB division. Obviously, we don't have access to the new initiatives and hiring plans that the management has in mind and this makes-up for part of the gap. Furthermore, IB market conditions stabilized but seems still fragile, so we would like to have more evidences of market trends at the beginning of 2020. For this reasons we estimate IB revenues at EUR23.8 million in 2022, almost in line with the 2018 level. All in all, we reach a 2022 total revenues of EUR66.3 million (as opposed to a guidance of EUR75 million) and a Net Income/revenues of 19.9% (as opposed to 20%

- of the guidance). With our new estimates we are able to see a 2022 dividend of EUR0.29 which would imply a yield >11% at current prices.
- > Recent evolution of the market and regulatory scenario is positive. Interestingly enough, with Equita openaly speaking about M&A, there were recently some deals in the Investment Banking arena: Mediobanca bought Messier Maris & Associates, a French boutique that shortly after the deal was announced gained to the Italian investment bank a place in the list of the advisors to the PSA-FCA merger. Houlihan Lokey, one of the comparable we use to value Equita, in October 2019 acquired Freeman & Co, a New York based independent advisory firm and added coverage in the FIG space. In a tough market boutiques may prefer to sell and converge into larger entities which, on their side, to balance revenues contraction may seek to expand in new niches. The other point to stress is that more and more often we hear about proposed changes to Mifid II, which on top of having negative impacts on brokers' financials, reported ample criticism over its effectiveness from investors, industry players and some regulators too. While we don't expect any short term decision nor massive benefits for industry partecipants, the fact that the regulation will not get worse is a positive news per-se. A reduction in bureaucracy is the main claim of the ones calling for a tweak to the rules.

Figure 2 - Old vs. new estimates

		2019E			2020E			2021E	
(EURm)	Old	New	% diff.	Old	New	% diff.	Old	New	% diff.
Revenues	54,9	52,5	-4,4%	58,3	57,6	-1,3%	61,4	61,7	0,5%
Profit before taxes	13,5	11,8	-12,6%	16,6	14,8	-10,6%	18,8	16,9	-10,2%
Profit before taxes %	24,5%	22,4%		28,4%	25,7%		30,6%	27,3%	
Net profit	9,6	8,1	-15,0%	11,8	10,3	-12,5%	13,3	11,7	-12,1%
Net profit adjusted	9,6	8,1	-15,0%	11,8	10,3	-12,5%	13,3	11,7	-12,1%


Source: UBI Banca estimates

Figure 3 - MTA traded volumes by semester (EURbn)



Source: Assosim


Figure 4 - Bond traded volumes by semester (EURbn)



Source: Assosim



Figure 5 - Average daily trading volumes on MTA (EURm)



Source: Borsa Italiana

Figure 6 - Average daily trading volumes for fixed income (EURm)



Source: Borsa Italiana

Valuation

- > Revising the target price to EUR3.37 (from EUR3.50). This is the result of a) the cut in estimates (-12.2% on average in 2019-22 at net income level); b) balanced by a 9% peers re-rating.
- > We reiterate our Buy rating (29% upside). While we acknowledge that the stock performance has been significantly negative, we believe this was due to end-market conditions. Management did all the right things to put the boat in the right direction. A market stabilization and the easy comparison approaching should ease tensions on the share price which, if the 2022 targets are considered, seems cheap. M&A appeal and the disclosure of performance fees could be other catalyst of a re-rating.

Figure 7 - Valuation summary

(EUR)	New	Old	% difference
P/BV	3,13	3,38	-7%
Peers	3,60	3,61	0%
Average	3,37	3,50	-4%

Source: Company data, UBI Banca estimates

Figure 8 - Peer based valuation

(EUR, x)	2019E	2020E
PE	16,5	14,9
Equita EPS	0,18	0,23
Equita fair value - A	2,95	3,37
Treasury shares - B	0,26	0,26
Equity co-invested - C	0,24	0,24
Pension liabilities - D	-0,05	-0,05
Equita Equity Value (A+B+C-D)	€ 3,40	€ 3,81

 ${\it Source: Company \ data, \ UBI \ Banca \ estimates, \ FactSet}$

Figure 9 - Peer Group multiples (priced on 14 November 2019)

Name	TIER	Price	Currency	Mkt Cap		P/Sales			P/E			P/BV			Div Yield	d
				million	2019E	2020E	2021E	2019E	2020E	2021E	2019E	2020E	2021E	2019E	2020E	2021E
Piper Jaffray	1	69,0	USD	991	1,4 x	1,0 x	1,0 x	11,9	10,2	10,0	1,4 x	1,4 x	1,3 x	3,3%	3,4%	3,8%
Numis Corp	1	2,8	GBP	290	2,2 x	1,6 x	na	24,6	22,9	na	1,8 x	na	na	5,1%	na	na
Evli Pankki Oyj	1	8,9	EUR	212	2,9 x	2,8 x	2,8 x	13,0	11,4	10,5	2,7 x	2,6 x	2,5 x	7,3%	7,7%	7,9%
Moelis	П	30,5	USD	1.901	2,7 x	2,3 x	2,2 x	14,3	12,8	12,7	5,5 x	4,8 x	6,6 x	7,2%	8,1%	8,9%
Evercore	П	68,6	USD	2.681	1,5 x	1,4 x	1,4 x	9,6	9,1	9,8	3,5 x	2,8 x	2,0 x	3,0%	3,3%	3,5%
Houlihan Lokey	П	42,7	USD	2.812	2,7 x	2,5 x	2,4 x	15,5	14,3	13,7	3,3 x	3,1 x	2,7 x	2,6%	2,9%	3,1%
DeA Capital	Ш	1,4	EUR	374	6,0 x	5,5 x	na	72,0	36,9	na	0,8 x	0,9 x	na	8,5%	7,8%	na
Tikehau Capital	Ш	23,7	EUR	3.230	7,9 x	6,5 x	5,5 x	19,7	16,8	13,2	1,0 x	1,0 x	1,0 x	3,0%	3,0%	3,3%
Azimut	Ш	22,8	EUR	3.319	3,4 x	3,5 x	3,3 x	11,5	14,8	14,2	4,3 x	4,1 x	3,7 x	5,4%	5,2%	5,3%
Average					2,7 x	2,5 x	2,4 x	14,3 x	14,3 x	12,7 x	2,7 x	2,7 x	2,5 x	5,0%	5,2%	5,1%
Equita Group		2,6	EUR	118	2,3 x	2,1 x	1,9 x	14,5 x	11,5 x	10,2 x	1,5 x	1,5 x	1,5 x	7,7%	8,5%	9,4%
Tier I					2,2 x	1,8 x	1,9 x	16,5 x	14,9 x	10,3 x	1,9 x	2,0 x	1,9 x	5,2%	5,5%	5,8%
Tier II					4,0 x	3,6 x	3,0 x	23,7 x	17,4 x	12,7 x	3,1 x	2,8 x	3,2 x	4,9%	5,1%	4,8%

Source: FactSet

Income Statement				
(EURm)	2018A	2019E	2020E	2021E
Global Markets	30,0	32,3	32,6	32,9
Investment Banking	26,1	15,1	17,4	20,4
Alternative Asset Management	3,7	5,0	7,5	8,5
Net Revenues	59,8	52,5	57,6	61,7
Personnel Costs	27,4	24,2	26,0	28,0
Administrative Expenses	16,8	16,6	16,8	16,9
Profit Before Taxes	15,6	11,8	14,8	16,9
% on Net Revenues	26,1%	22,4%	25,7%	27,3%
Income Taxes	4,5	3,7	4,5	5,1
Group Net Profit	11,0	8,1	10,3	11,7
Non-recurring	0,9	0,0	0,0	0,0
Group Net Profit - Adjusted	12,0	8,1	10,3	11,7

Source: Company data, UBI Banca estimates

Da	lance	Ch	4
Ви	инсе	311	eei

(EURm)	2018A	2019E	2020E	2021E
Financial Assets at FV through P&L	60,5	62,2	64, I	66,0
Financial Assets at Amortised Cost	215,1	221,0	230,4	240,7
Equity Investments	1,5	1,5	1,5	1,5
Tangible Assets	0,6	0,6	0,6	0,6
Intangible Assets	15,0	15,0	15,0	15,0
Tax Assets	3,9	3,9	3,9	3,9
Other Assets	1,7	1,7	1,7	1,7
Total Assets	298,3	306,0	317,2	329,4
Financial Liabilities at Amort. Cost	184,8	194,0	203,7	213,9
Financial Liabilities Held for Trad.	8,3	8,6	8,9	9,2
Tax Liabilities	2,0	2,0	2,0	2,0
Other Liabilities	14,5	14,5	14,5	14,5
Employees' Termination Indemnities	2,4	2,4	2,4	2,4
Allowances for Risks and Charges	6,2	6,2	6,2	6,2
Equity	80, I	78,2	79,4	81,1
Total Liabilities and Equity	298,3	306,0	317,2	329,4



Financial Ratios				
(%)	2018A	2019E	2020E	2021E
TCR	25,2%	25,8%	25,1%	24,5%
CETI ratio	25,2%	25,8%	25,1%	24,5%
RoE	13,8%	10,4%	13,0%	14,5%
RoTE	20,4%	14,8%	19,1%	21,6%
Cost/Income	73,9%	77,6%	74,3%	72,7%
Comp/Revenues	45,8%	46,0%	45,2%	45,3%
Payout	90,7%	111,9%	97,1%	95,0%

Source: Company data, UBI Banca estimates

Dor	Share	Data
rer	Snare	Data

(EUR)	2018A	2019E	2020E	2021E
EPS - reported	0,24	0,18	0,23	0,26
EPS - adjusted	0,26	0,18	0,23	0,26
DPS	0,22	0,20	0,22	0,25
BVPS - ex-treasury	1,76	1,72	1,75	1,78
TBVPS - ex treasury	1,44	1,43	1,39	1,42

Source: Company data, UBI Banca estimates

Stock Market Ratios

(X)	2018A *	2019E	2020E	2021E
P/E	13,2	14,5	11,5	10,1
P/E Adjusted	12,2	14,5	11,5	10,1
P/BV	1,8	1,5	1,5	1,5
P/TBV	2,2	1,8	1,9	1,8
Dividend Yield (%)	6,9%	7,7%	8,5%	9,4%
RoE/CoE	2,0	1,5	1,9	2,1

Source: Company data, UBI Banca estimates

* Based on 2018 average price

Growth rates

(%)	2018A	2019E	2020E	2021E
Revenues	10,9%	-12,2%	9,7%	7,2%
Profit Before Taxes	1,6%	-24,5%	25,8%	13,8%
Net Income	0,2%	-26,3%	26,7%	13,8%
Net Income Adjusted	6,6%	-32,0%	26,7%	13,8%



Disclaimer

Analyst Declaration

This research report (the "Report") has been prepared by Massimo Vecchio and Dario Fasani on behalf of UBI Banca S.p.A. ("UBI Banca") in the context of the ancillary service provided by UBI Banca named "Investment research and financial analysis or other forms of recommendation relating to transactions in financial instruments" under Paragraph 5), Section B, Annex I of the Directive 2014/65/EU ("MiFID II"). UBI Banca is an Italian bank under art. 4 (1)(27) of MiFID II and it is supervised by the European Central Bank and duly authorised to provide investment services pursuant to Article 1, Paragraph 5, letter a), b), c), c-bis), e) and f) of the Legislative Decree 24 February 1998, n° 58 under the supervision of the Italian Authority for the financial markets (Consob). UBI Banca has its head office at Piazza Vittorio Veneto 8, 24122 Bergamo.

The analysts who prepared the Report, and whose names and roles appear on the front page, certify that:

- a. the views expressed on the company mentioned herein (the "Company") accurately reflects their personal views. It does not represent the views or opinions of UBI Banca, its management or any other company which is part of or affiliated to the UBI Banca group (the "UBI Banca Group"). It may possible that some UBI Banca Group's officers may disagree with the views expressed in this Report;
- b. they have not received and will not receive any direct or indirect compensation in exchange for any views expressed in this Report;
- c. the analysts do not own any securities and/or any other financial instrument issued by the Company or any financial instrument whose price depends on or is linked to any securities and/or any financial instrument issued by the Company;
- d. neither the analysts nor any member of the analysts' household serves as an officer, director or advisory board member of the Company;
- the remuneration of the analysts is not directly tied to transactions in services of investment firms or other type of transactions it or any legal person part of the same group performs, or to trading fees it or any legal person that is part of the same group receives;
- f. Massimo Vecchio is member of AIAF's Directive Counsel.

General disclosure

This Report is for information purposes only. This Report (i) is not, nor may it be construed, to constitute, an offer for sale or subscription of or a solicitation of any offer to buy or subscribe for any securities issued or to be issued by the Company, (ii) should not be regarded as a substitute for the exercise of the recipient's own judgement. In addition, the information included in this Report may not be suitable for all recipients. Therefore the recipient should conduct his own investigations and analysis of the Company and securities referred to in this document and make his own investment decisions without undue reliance on its contents. Neither UBI Banca, nor any other company belonging to the UBI Banca Group, nor any of its directors, managers, officers or employees, accepts any direct or indirect liability whatsoever (in negligence or otherwise), and accordingly no direct or indirect liability whatsoever shall be assumed by, or shall be placed on, UBI Banca, or any other company belonging to the UBI Banca Group, or any of its directors, managers, officers or employees, for any loss, damage, cost, expense, lower earnings howsoever arising from any use of this Report or its contents or otherwise arising in connection with this Report.

The information provided and the opinions expressed in this Report are based upon

information and data provided to the public by the Company or news otherwise public and refers to the date of publication of the Report. The sources (press publications, financial statements, current and periodic releases, as well as meetings and telephone conversations with the Company's representatives) are believed to be reliable and in good faith, but no representation or warranty, express or implied, is made by UBI Banca as to their accuracy, completeness or correctness. Past performance is not a guarantee of future results. Any opinions, forecasts or estimates contained herein constitute a judgement as at the date of this Report, and there can be no assurance that the future results of the Company and/or any future events involving directly or indirectly the Company will be consistent with any such opinions, forecasts or estimates. Any information herein is subject to change, update or amendment without notice by UBI Banca subsequent to the date of this Report, with no undertaking by UBI Banca to notify the recipient of this Report of such change, update or amendment.

This document was sent to the Issuer alone in the draft version for the sole purpose of verifying the correctness of the factual data contained therein and was subject to modification exclusively in relation to these factual elements.

Organizational and administrative arrangements to prevent conflicts of interests

UBI Banca maintains procedures and organizational mechanism (physical and non physical barriers designed to restrict the flow of information between the unit which performs investment research activity and other units of UBI Banca) to prevent and professionally manage conflicts of interest in relation to investment research in accordance with art. 23 of Directive 2014/65/EU and under art. 34 (3) and art. 37 of the Regulation 2017/565/EU.

More specifically, UBI Banca has established, implements and maintains an effective conflicts of interests policy aimed at preventing and managing the potential conflicts of interest that could occur during the performance of the investment research services.

Insofar as the above mentioned organizational and administrative arrangements established by UBI Banca to prevent or manage potential conflicts of interests are not sufficient to ensure, with reasonable confidence, that risks of damage to the interests of the client will be prevented, UBI Banca engages to provide a clear disclosure of the specific conflicts of interests arising of the performance of investment research services, including a description of the sources of those conflicts and the steps undertaken to mitigate them, taking into account the nature of the client to whom the disclosure is being made.

For further information please see UBI Banca's website (www.ubibanca.com/equity-research - "Informativa sintetica sull'attività di ricerca") and (www.ubibanca.com/Mifid - "Policy sintetica conflitti di interessi"). More details about the conflicts of interests policy will be provided by UBI Banca upon request.

Disclosure of interests and conflicts of interests pursuant to Delegated Regulation 2016/958/EU

In relation to the Company the following interest/conflict of interest have been found:

- > UBI Banca acts as Specialist for Equita Group
- > UBI Banca may have long or short positions with the issuer

On the basis of the checks carried out no other interest/conflict of interest arose.



Frequency of updates

UBI Banca aims to provide continuous coverage of the companies in conjunction with the timing of periodical accounting reports and any exceptional event that occurs affecting the issuer's sphere of operations and in any case at least twice per year. The companies for which UBI Banca acts as Sponsor or Specialist are covered in compliance with regulations of the market authorities.

For further information please refer to www.ubibanca.com/equity-research.

Valuation methodology

UBI Banca's analysts value the Company subject to their recommendations using several methods among which the most prevalent are: the Discounted Cash Flow method (DCF), the Economic Value Added method (EVA), the Multiple comparison method, the SOP method and the NAV method.

The analysts use the above valuation methods alternatively and/or jointly at their discretion. The assigned target price may differ from the fair value, as it also takes into account overall market/sector conditions, corporate/market events, and corporate specifics (i.e. holding discounts) reasonably considered to be possible drivers of the company's share price performance. These factors may also be assessed using the methodologies indicated above.

For further information please refer to www.ubibanca.com/equity-research.

Ranking system

UBI Banca's analysts use an "absolute" rating system, not related to market performance. The explanation of the rating system is listed below:

Buy: if the target price is 15% higher than the market price, over the next 12 months.

Hold: if the target price is 15% below or 15% above the market price, over the next 12 months.

Sell: if the target price is 15% lower than the market price, over the next 12 months.

No Rating: the investment rating and target price have been suspended as there is not sufficient fundamental basis for determining an investment rating or target. The previous investment rating and target price, if any, are no longer in effect. Alternatively, No Rating is assigned in certain circumstances when UBI Banca is acting in any advisory capacity in a strategic transaction involving the Company.

Target price: the market price that the analyst believes that the share may reach within a one-year time horizon.

Market price: closing price on the day before the issue date of the report, appearing on the first page.

Distribution

Italy: This document is intended for distribution in electronic form to "Professional Clients" and "Qualified Counterparties" as defined by Legislative Decree 24 February 1998, n. 58 and by Consob Regulation n. 16190 dated 29.10.2007, as further amended and supplemented.

This Report has been released within 30 minutes from the timing reported on the front page.



IN THE UNITED KINGDOM, THIS DOCUMENT IS BEING DISTRIBUTED ONLY TO, AND IS DIRECTED ONLY AT PERSONS WHO (A) ARE (I) PERSONS FALLING WITHIN ARTICLE 19 OR ARTICLE 49 OF THE FINANCIAL SERVICES AND MARKETS ACT 2000 (FINANCIAL PROMOTION) ORDER 2005 (AND ONLY WHERE THE CONDITIONS CONTAINED IN THOSE ARTICLES HAVE BEEN, OR WILL AT THE RELEVANT TIME BE, SATISFIED) OR (II) ANY OTHER PERSONS TO WHOM IT MAY BE LAWFULLY COMMUNICATED; AND (B) ARE QUALIFIED INVESTORS WITHIN THE MEANING OF ARTICLE 2(1)(E) OF THE PROSPECTUS DIRECTIVE (DIRECTIVE 2003/71/EC), (ALL SUCH PERSONS BEING REFERRED TO AS "RELEVANT PERSONS"). THIS DOCUMENT MUST NOT BE ACTED ON OR RELIED ON BY PERSONS WHO ARE NOT RELEVANT PERSONS.

THIS REPORT DOES NOT CONSTITUTE A PROSPECTUS WITHIN THE MEANING OF ARTICLE 652A OR ART. 1156 OF THE SWISS CODE OF OBLIGATIONS OR A LISTING PROSPECTUS WITHIN THE MEANING OF THE LISTING RULES OF THE SIX SWISS EXCHANGE OR ANY OTHER TRADING VENUE IN SWITZERLAND, OR A SIMILAR COMMUNICATION WITHIN THE MEANING OF ART. 752 THE SWISS CODE OF OBLIGATIONS, AND HAS BEEN PREPARED WITHOUT REGARD TO SWISS LAWS AND REGULATIONS, AND DOES NOT CONSTITUTE AN OFFER TO SUBSCRIBE FOR, BUY OR OTHERWISE ACQUIRE ANY SECURITIES OF THE COMPANY.

Copyright

This Report is being supplied solely for the recipient's information and may not be reproduced, redistributed or passed on, directly or indirectly to any other person or published, in whole or in part, for any purpose without prior written consent of UBI Banca.

The copyright and intellectual property rights on the data are owned by UBI Banca Group, unless otherwise indicated. The data, information, opinions and valuations contained in this Report may not be subject to further distribution or reproduction, in any form or via any means, even in part, unless expressly consented by UBI Banca.

By accepting this Report the recipient agrees to be bound by all of the forgoing provisions.

Distribution of ratings

Equity rating dispersion in the past 12 months					
Buy	Hold	Sell	No Rating		
91.2%	7.0%	1.8%	0.0%		

Proportion on issuers to which UBI Banca has supplied investment banking services relating to the last 12 months

Buy	Hold	Sell	No Rating
82.5%	100%	100%	-%

For further information regarding yearly and quarterly rating statistics and descriptions, please refer to www.ubibanca.com/equity-research.

Historical ratings and target prices

Date	Rating	Target Price (EUR)	Market Price (EUR)
9 May 2019	BUY	3.57	3.02
12 September 2019	BUY	3.50	2.68